Plus   Neg

Graco Q4 Profit Tops Estimates; Shares Surge - Quick Facts

Graco Inc. (GGG) reported fourth-quarter adjusted net earnings per share of $0.48, up 12 percent from prior year. On average, 9 analysts polled by Thomson Reuters expected the company to report profit per share of $0.39 for the quarter. Analysts' estimates typically exclude special items.

Sales for the quarter increased 1 percent (2 percent at consistent translation rates) year-on-year to $412.29 million. Analysts expected revenue of $392.62 million for the quarter.

For 2020, the company projects low single-digit revenue growth on an organic, constant currency basis.

Shares of Graco Inc. were up nearly 5% after hours.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered. Gilead Sciences Inc. said it is donating its existing supply of 1.5 million individual doses of remdesivir, its investigational medicine for coronavirus or Covid-19. The drug, which is yet to get regulatory approval, is available for compassionate use, expanded access and clinical trials to treat patients with the most severe symptoms of COVID-19.
Follow RTT